Vietnam's Biotech Leap: Porcine Corneas Offer New Sight and Strategic Vision

HO CHI MINH CITY, Vietnam – July 13, 2026 – For hundreds of thousands of people in Vietnam living in darkness, a new dawn is breaking. A strategic partnership between Vietnam Gene & Cell Technology (VGCT), a member of the deep-tech conglomerate CT Group, and the state-run National Eye Hospital has yielded a medical breakthrough: the successful transplantation of bioengineered porcine corneas into human recipients. This development offers a tangible solution to a desperate public health crisis and signals a major strategic shift in Vietnam's technological and economic ambitions.

The scale of the problem is immense. An estimated 500,000 people in Vietnam and over 6 million across the ASEAN region are blind due to corneal disease and require transplantation. Yet, the supply of human donor corneas is critically low. Between 2023 and 2025, Vietnam's Eye Bank received only around 300 corneas, leaving a vast and growing waiting list of patients with little hope. Many have waited for decades.

"The availability of an additional source of replacement corneas will represent a major breakthrough for ophthalmology," said Assoc. Prof. Dr. Pham Ngoc Dong, Director of the National Eye Hospital, at a recent signing ceremony. The collaboration, he noted, provides an opportunity to access "one of modern medicine's most significant achievements."

The Science of Sight: From Porcine Tissue to Human Vision

The innovation at the heart of this breakthrough is not merely a transplant but a sophisticated feat of bioengineering. The new corneas are not whole pig organs but are constructed from medical-grade Type I collagen, the same primary protein found in the human cornea, which is sourced from purified pig skin—a readily available byproduct of the food industry.

The core scientific process is decellularization. Technicians strip the porcine tissue of all pig cells and genetic material, leaving behind a pure, biocompatible collagen scaffold. This is the critical step in mitigating the primary risk of any cross-species transplant: immune rejection. By removing the cells that a recipient's body would identify as foreign, the procedure dramatically lowers the chance of rejection. The cornea's natural state as an "immune-privileged" site, with a limited inflammatory response, further aids the implant's success.

Early clinical data is highly encouraging. Follow-up results after 12 months in an initial patient cohort showed a graft survival rate of 94.7%, with 18 out of 19 patients regaining functional vision. These outcomes align with similar international studies, where some patients have achieved 20/20 vision after receiving comparable implants. A key benefit is the reduced need for long-term immunosuppressant drugs, a standard requirement for human-to-human organ transplants that carries its own set of health risks.

While the risk of transmitting animal-borne pathogens (xenozoonosis), such as porcine endogenous retroviruses (PERVs), is a theoretical concern in all xenotransplantation, experts note it is considered extremely low for acellular corneal grafts. Stringent biosecurity protocols and the use of pathogen-free animal sources are standard practice, and to date, no such transmission has been documented in corneal xenotransplantation trials globally.

A Strategic Blueprint: The 'Triple-Helix' Model for Innovation

This medical achievement is also a case study in national strategy. The collaboration is a prime example of a Public-Private Partnership (PPP) operating under a 'triple-helix' model, weaving together private enterprise (VGCT and CT Group), government institutions (National Eye Hospital, Ministry of Health), and academia. This framework is designed to de-risk and accelerate deep-tech innovation, transforming laboratory concepts into market-ready solutions.

Dr. Dang Thi Tuoi, Deputy General Director of VGCT, emphasized the partnership's expansive value. "The greatest value of this partnership lies not only in contributing to GDP by enabling hundreds of thousands of people to return to work... but also in jointly building research capabilities, mastering core technologies, and establishing an effective public-private partnership model," she stated. The success of this model, she hopes, will be a replicable blueprint for other high-stakes biomedical fields in Vietnam.

Behind VGCT is the strategic and financial weight of its parent, CT Group. The conglomerate's decade-long investment in R&D, production, and commercialization infrastructure underscores a long-term vision. This is not a speculative venture but a calculated move to establish Vietnam as a hub of high-value biotechnology. By focusing on cutting-edge fields like xenotransplantation, CAR-T cell therapy, and stem cells, the group is positioning itself and the nation to compete in the global knowledge economy.

Navigating the Path to Market: Regulation, Scalability, and Access

With successful human trials complete, the path to widespread clinical use is now a question of regulation and logistics. VGCT has formally submitted a market authorization dossier to Vietnam's Ministry of Health, a crucial step toward making the procedure widely available. However, experts caution that the rollout must be meticulous.

Professor Tôn Thị Kim Thanh, head of the Vietnam Ophthalmological Society, has stressed the need for a phased clinical introduction, standardized training protocols for surgeons, and robust post-market surveillance to ensure long-term patient safety and efficacy. This measured approach is essential for building public and clinical trust in a groundbreaking technology.

The bioengineered corneas present significant logistical advantages over donated human tissue. They can be stored for up to two years, compared to just two weeks for human corneas, eliminating a major bottleneck in supply chain management. Furthermore, the use of an inexpensive and abundant raw material suggests the potential for a more cost-effective solution, which could radically improve accessibility for patients across different economic strata. The development of minimally invasive surgical techniques associated with these implants may also allow the procedure to be performed in a wider range of clinical settings, not just highly specialized urban hospitals.

Vietnam's Vision for a Biotech Future

This achievement does more than solve a medical problem; it places Vietnam firmly on the regional map for biomedical innovation, alongside countries like South Korea and China that are also conducting human trials in corneal xenotransplantation. It demonstrates a national capacity to move beyond manufacturing and assembly into the realm of deep-tech R&D and value creation.

The successful development of bioengineered corneas is a powerful proof of concept for VGCT and its parent, CT Group. It validates their long-term investment and strategic focus on a portfolio of next-generation medical technologies. For Vietnam, it represents a significant step toward achieving strategic autonomy in a critical sector, reducing reliance on foreign technology and building a resilient, knowledge-based economy that can address its own public health challenges while simultaneously creating high-value exports for the broader ASEAN region and the world.